David Schlanger became WebMD’s CEO in August of 2013, but first joined the company in 1995, after serving as executive director, business development at Merck.
David Schlanger became WebMD’s CEO in August of 2013, but first joined the company in 1995, after serving as executive director, business development at Merck.
The commercialization of pharmaceutical drugs has changed a lot in two decades: industry’s focus on specialty drugs for smaller populations and patients with chronic disease has supplanted the emphasis on big name primary care products, and the blanket TV buys that propelled them into blockbuster glory.
David Schlanger
Schlanger says he chuckles when he sees Abbvie’s TV ad pushing Humira for Crohn’s disease-”there’s only 2 million people with Crohn’s disease” in the US-because it stands as a relic of a bygone era where the biggest media spend all but guaranteed the largest chunk of the market. Money still talks, of course, but fewer patients are all tuned in to the same listening apparatus. Physicians and patients still need to be educated about prescription drugs, but with limited access to the former, and a larger cost burden placed on the latter, drug companies hoping to reach their target audiences (and target sales revenues) do better by concentrating on the quality of interaction, not the quantity of exposure.
For Pharm Exec’s Q&A with David Schlanger, click here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.